title: Dose-intense cyclophosphamide and etoposide for patients with refractory or high-risk non-Hodgkin's lymphoma.
authors.affiliation: Department of Medicine, Division of Medical Oncology and Stem Cell Transplantation, Duke University Medical Center, Durham, NC 27710, USA.
authors.forename: Jeffrey
authors.initials: J
authors.lastname: Talbot
authors.forename: Valerie K
authors.initials: VK
authors.lastname: Ibom
authors.forename: David A
authors.initials: DA
authors.lastname: Rizzieri
authors.forename: Robert
authors.initials: R
authors.lastname: Barrier
authors.forename: Donna
authors.initials: D
authors.lastname: Niedzwieki
authors.forename: Carlos M
authors.initials: CM
authors.lastname: DeCastro
authors.forename: Joseph O
authors.initials: JO
authors.lastname: Moore
authors.forename: Patrick
authors.initials: P
authors.lastname: Buckley
authors.forename: Rhonda
authors.initials: R
authors.lastname: Laney
authors.forename: Diane
authors.initials: D
authors.lastname: Stevenson
authors.forename: Heather
authors.initials: H
authors.lastname: Rumbaugh
authors.forename: Jon P
authors.initials: JP
authors.lastname: Gockerman
mesh_terms: D000328:Adult; D000368:Aged; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000008:administration & dosage*; D019008:Drug Resistance, Neoplasm; D005047:Etoposide / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D012074:Remission Induction; D012306:Risk; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D018906:Antineoplastic Agents, Alkylating; D000972:Antineoplastic Agents, Phytogenic; D005047:Etoposide; D003520:Cyclophosphamide